Clinical value of BRAF V600E in thyroid carcinoma and the effect of telomerase reverse transcriptase promoter mutations / 生物医学工程学杂志
Journal of Biomedical Engineering
;
(6): 338-342, 2019.
Article
Dans Chinois
| WPRIM
| ID: wpr-774201
ABSTRACT
In recent years, the incidence of thyroid cancer has been increasing. Researchers around the world have begun to pay more attention to the exploration of its pathogenesis, disease evolution and prognosis. Among them, research in the field of gene molecules has become a hotspot, which includes the mutations of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) and the telomerase reverse transcriptase (TERT) promoter. However, this field is not mature, and there are many problems and challenges need to be solved. This paper explores the value of BRAF mutation in the treatment, recurrence, mortality and prognosis of papillary thyroid carcinoma. In addition, we also explore the relationship between BRAF mutation and TERT promoter mutations and their influences in thyroid cancer. We hope this paper could help later scholars understand the current situation in this field and find a research direction in the future.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs de la thyroïde
/
Régions promotrices (génétique)
/
Telomerase
/
Protéines proto-oncogènes B-raf
/
Génétique
/
Mutation
Limites du sujet:
Animaux
/
Humains
langue:
Chinois
Texte intégral:
Journal of Biomedical Engineering
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS